CMN-005 by CoImmune for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for B-Cell Non-Hodgkin Lymphoma.

Levels of anxiety among 9-11 year old’s may instigate parental digital interruptions

Researchers examined the prospective associations between perceived parental digital interruptions and mental health symptoms in emerging adolescents.

August 21, 2024

Tim Walz Beat COVID Skeptic Doc in 2022 Race for Governor

Minnesota Gov. Tim Walz (D) — who is now Kamala Harris’ pick for vice president — won reelection in 2022 after defeating Scott Jensen, MD,

August 7, 2024

Eliem Therapeutics agrees to acquire Tenet

Share this article The combined company will advance the clinical development of TNT119 for autoimmune diseases. Credit: Dragana Gordic / Shutterstock.com. US-based Eliem Therapeutics has

April 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.